New oral GLP-1 drug delivers up to 12% weight loss in 36 weeks

A new strategy for delivering GLP-1 drugs to patients with obesity or who were overweight resulted in up to a 12% reduction in body weight after 36 weeks, according to a randomized phase II clinical trial published in Nature ...

The GLP-1 paradox: Weight loss drugs may lead to stigma

Glucagonlike peptide-1 (GLP-1) medications have taken over the national conversation around weight loss. From celebrity headlines to everyday conversations, GLP-1 drugs like Ozempic and Wegovy are often framed as breakthroughs ...

Unexpected brain mechanism challenges assumptions about GLP-1s

For decades, obesity medications produced only modest weight loss. But in recent years, Ozempic and related GLP-1 therapies have transformed the field, enabling sustained weight loss of 10% to 15% or more. Despite their success, ...

AI atlas reveals hidden whole-body-damage caused by obesity

Obesity affects far more than metabolism and fat storage. It alters immune activity, nerve structure, and tissue organization across multiple organ systems, increasing the risk of diseases including type 2 diabetes, cardiovascular ...

page 3 from 40